Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease
In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAF...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry and laboratory medicine 2022-01, Vol.60 (2), p.243-251 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 251 |
|---|---|
| container_issue | 2 |
| container_start_page | 243 |
| container_title | Clinical chemistry and laboratory medicine |
| container_volume | 60 |
| creator | Pitkänen, Niina Finkenstedt, Armin Lamina, Claudia Juonala, Markus Kähönen, Mika Mäkelä, Kari-Matti Dieplinger, Benjamin Viveiros, Andre Melmer, Andreas Leitner, Isabella Kedenko, Ludmilla Seppälä, Ilkka Viikari, Jorma S.A. Mueller, Thomas Kronenberg, Florian Paulweber, Bernhard Lehtimäki, Terho Zoller, Heinz Raitakari, Olli T. Dieplinger, Hans |
| description | In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD.
Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up.
Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p |
| doi_str_mv | 10.1515/cclm-2021-0837 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2605230968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2605230968</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-8fe82e750511a780020c921958f62318f994e572c5d1aa1a1dca9a440eb3e7c43</originalsourceid><addsrcrecordid>eNptkU1Lw0AQhhdRbK1ePUrAi5fUnf1KAl5E_IKCHvQctpuJ3bJJ6m6i9N-btFVBPM0MPPsO8ywhp0CnIEFeGuOqmFEGMU15skfGIHgSC85hf9OLWCkGI3IUwpJSkFIkh2TERSqpAjkmz9elrmwdrTwW1rQhahc4DB_aYW0w0nUR2drYYjM1ZVQ3tXamWTTOmqjUbbuOnP1AHxU2oA54TA5K7QKe7OqEvN7dvtw8xLOn-8eb61lsBKg2TktMGSaSSgCdpJQyajIGmUxLxTikZZYJlAkzsgCtQUNhdKaFoDjnmBjBJ-Rim7vyzXuHoc0rGww6p2tsupAzRSXjNFNpj57_QZdN5_szBgqUEJKLpKemW8r4JgSPZb7yttJ-nQPNB9f54DofXOeD6_7B2S62m1dY_ODfcnvgagt8ateiL_DNd-u--V3_f7KijPU_-AUzqYzb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616445347</pqid></control><display><type>article</type><title>Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease</title><source>MEDLINE</source><source>De Gruyter journals</source><creator>Pitkänen, Niina ; Finkenstedt, Armin ; Lamina, Claudia ; Juonala, Markus ; Kähönen, Mika ; Mäkelä, Kari-Matti ; Dieplinger, Benjamin ; Viveiros, Andre ; Melmer, Andreas ; Leitner, Isabella ; Kedenko, Ludmilla ; Seppälä, Ilkka ; Viikari, Jorma S.A. ; Mueller, Thomas ; Kronenberg, Florian ; Paulweber, Bernhard ; Lehtimäki, Terho ; Zoller, Heinz ; Raitakari, Olli T. ; Dieplinger, Hans</creator><creatorcontrib>Pitkänen, Niina ; Finkenstedt, Armin ; Lamina, Claudia ; Juonala, Markus ; Kähönen, Mika ; Mäkelä, Kari-Matti ; Dieplinger, Benjamin ; Viveiros, Andre ; Melmer, Andreas ; Leitner, Isabella ; Kedenko, Ludmilla ; Seppälä, Ilkka ; Viikari, Jorma S.A. ; Mueller, Thomas ; Kronenberg, Florian ; Paulweber, Bernhard ; Lehtimäki, Terho ; Zoller, Heinz ; Raitakari, Olli T. ; Dieplinger, Hans</creatorcontrib><description>In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD.
Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up.
Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23-1.54] per 10 mg/L increase, p<0.0001).
Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/cclm-2021-0837</identifier><identifier>PMID: 34850615</identifier><language>eng</language><publisher>Germany: De Gruyter</publisher><subject>Adult ; afamin ; Austria - epidemiology ; Cardiovascular diseases ; Carrier Proteins - blood ; Diabetes mellitus (non-insulin dependent) ; Fatty liver ; Female ; Finland - epidemiology ; Glycoproteins - blood ; Health risks ; Humans ; Incidence ; Liver ; Liver diseases ; Male ; Metabolic disorders ; Metabolic syndrome ; Non-alcoholic Fatty Liver Disease - blood ; Non-alcoholic Fatty Liver Disease - diagnosis ; Non-alcoholic Fatty Liver Disease - epidemiology ; non-alcoholic liver disease ; Population ; Population-based studies ; prediction ; Prevalence ; Regression analysis ; Risk Factors ; Serum Albumin, Human ; Sex ; vitamin E-binding protein</subject><ispartof>Clinical chemistry and laboratory medicine, 2022-01, Vol.60 (2), p.243-251</ispartof><rights>2021 Niina Pitkänen et al., published by De Gruyter, Berlin/Boston.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-8fe82e750511a780020c921958f62318f994e572c5d1aa1a1dca9a440eb3e7c43</citedby><cites>FETCH-LOGICAL-c416t-8fe82e750511a780020c921958f62318f994e572c5d1aa1a1dca9a440eb3e7c43</cites><orcidid>0000-0002-4484-8471</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2021-0837/pdf$$EPDF$$P50$$Gwalterdegruyter$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/cclm-2021-0837/html$$EHTML$$P50$$Gwalterdegruyter$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27901,27902,66497,68281</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34850615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pitkänen, Niina</creatorcontrib><creatorcontrib>Finkenstedt, Armin</creatorcontrib><creatorcontrib>Lamina, Claudia</creatorcontrib><creatorcontrib>Juonala, Markus</creatorcontrib><creatorcontrib>Kähönen, Mika</creatorcontrib><creatorcontrib>Mäkelä, Kari-Matti</creatorcontrib><creatorcontrib>Dieplinger, Benjamin</creatorcontrib><creatorcontrib>Viveiros, Andre</creatorcontrib><creatorcontrib>Melmer, Andreas</creatorcontrib><creatorcontrib>Leitner, Isabella</creatorcontrib><creatorcontrib>Kedenko, Ludmilla</creatorcontrib><creatorcontrib>Seppälä, Ilkka</creatorcontrib><creatorcontrib>Viikari, Jorma S.A.</creatorcontrib><creatorcontrib>Mueller, Thomas</creatorcontrib><creatorcontrib>Kronenberg, Florian</creatorcontrib><creatorcontrib>Paulweber, Bernhard</creatorcontrib><creatorcontrib>Lehtimäki, Terho</creatorcontrib><creatorcontrib>Zoller, Heinz</creatorcontrib><creatorcontrib>Raitakari, Olli T.</creatorcontrib><creatorcontrib>Dieplinger, Hans</creatorcontrib><title>Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clin Chem Lab Med</addtitle><description>In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD.
Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up.
Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23-1.54] per 10 mg/L increase, p<0.0001).
Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort.</description><subject>Adult</subject><subject>afamin</subject><subject>Austria - epidemiology</subject><subject>Cardiovascular diseases</subject><subject>Carrier Proteins - blood</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Finland - epidemiology</subject><subject>Glycoproteins - blood</subject><subject>Health risks</subject><subject>Humans</subject><subject>Incidence</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Non-alcoholic Fatty Liver Disease - blood</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Non-alcoholic Fatty Liver Disease - epidemiology</subject><subject>non-alcoholic liver disease</subject><subject>Population</subject><subject>Population-based studies</subject><subject>prediction</subject><subject>Prevalence</subject><subject>Regression analysis</subject><subject>Risk Factors</subject><subject>Serum Albumin, Human</subject><subject>Sex</subject><subject>vitamin E-binding protein</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1Lw0AQhhdRbK1ePUrAi5fUnf1KAl5E_IKCHvQctpuJ3bJJ6m6i9N-btFVBPM0MPPsO8ywhp0CnIEFeGuOqmFEGMU15skfGIHgSC85hf9OLWCkGI3IUwpJSkFIkh2TERSqpAjkmz9elrmwdrTwW1rQhahc4DB_aYW0w0nUR2drYYjM1ZVQ3tXamWTTOmqjUbbuOnP1AHxU2oA54TA5K7QKe7OqEvN7dvtw8xLOn-8eb61lsBKg2TktMGSaSSgCdpJQyajIGmUxLxTikZZYJlAkzsgCtQUNhdKaFoDjnmBjBJ-Rim7vyzXuHoc0rGww6p2tsupAzRSXjNFNpj57_QZdN5_szBgqUEJKLpKemW8r4JgSPZb7yttJ-nQPNB9f54DofXOeD6_7B2S62m1dY_ODfcnvgagt8ateiL_DNd-u--V3_f7KijPU_-AUzqYzb</recordid><startdate>20220127</startdate><enddate>20220127</enddate><creator>Pitkänen, Niina</creator><creator>Finkenstedt, Armin</creator><creator>Lamina, Claudia</creator><creator>Juonala, Markus</creator><creator>Kähönen, Mika</creator><creator>Mäkelä, Kari-Matti</creator><creator>Dieplinger, Benjamin</creator><creator>Viveiros, Andre</creator><creator>Melmer, Andreas</creator><creator>Leitner, Isabella</creator><creator>Kedenko, Ludmilla</creator><creator>Seppälä, Ilkka</creator><creator>Viikari, Jorma S.A.</creator><creator>Mueller, Thomas</creator><creator>Kronenberg, Florian</creator><creator>Paulweber, Bernhard</creator><creator>Lehtimäki, Terho</creator><creator>Zoller, Heinz</creator><creator>Raitakari, Olli T.</creator><creator>Dieplinger, Hans</creator><general>De Gruyter</general><general>Walter De Gruyter & Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4484-8471</orcidid></search><sort><creationdate>20220127</creationdate><title>Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease</title><author>Pitkänen, Niina ; Finkenstedt, Armin ; Lamina, Claudia ; Juonala, Markus ; Kähönen, Mika ; Mäkelä, Kari-Matti ; Dieplinger, Benjamin ; Viveiros, Andre ; Melmer, Andreas ; Leitner, Isabella ; Kedenko, Ludmilla ; Seppälä, Ilkka ; Viikari, Jorma S.A. ; Mueller, Thomas ; Kronenberg, Florian ; Paulweber, Bernhard ; Lehtimäki, Terho ; Zoller, Heinz ; Raitakari, Olli T. ; Dieplinger, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-8fe82e750511a780020c921958f62318f994e572c5d1aa1a1dca9a440eb3e7c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>afamin</topic><topic>Austria - epidemiology</topic><topic>Cardiovascular diseases</topic><topic>Carrier Proteins - blood</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Finland - epidemiology</topic><topic>Glycoproteins - blood</topic><topic>Health risks</topic><topic>Humans</topic><topic>Incidence</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Non-alcoholic Fatty Liver Disease - blood</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Non-alcoholic Fatty Liver Disease - epidemiology</topic><topic>non-alcoholic liver disease</topic><topic>Population</topic><topic>Population-based studies</topic><topic>prediction</topic><topic>Prevalence</topic><topic>Regression analysis</topic><topic>Risk Factors</topic><topic>Serum Albumin, Human</topic><topic>Sex</topic><topic>vitamin E-binding protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pitkänen, Niina</creatorcontrib><creatorcontrib>Finkenstedt, Armin</creatorcontrib><creatorcontrib>Lamina, Claudia</creatorcontrib><creatorcontrib>Juonala, Markus</creatorcontrib><creatorcontrib>Kähönen, Mika</creatorcontrib><creatorcontrib>Mäkelä, Kari-Matti</creatorcontrib><creatorcontrib>Dieplinger, Benjamin</creatorcontrib><creatorcontrib>Viveiros, Andre</creatorcontrib><creatorcontrib>Melmer, Andreas</creatorcontrib><creatorcontrib>Leitner, Isabella</creatorcontrib><creatorcontrib>Kedenko, Ludmilla</creatorcontrib><creatorcontrib>Seppälä, Ilkka</creatorcontrib><creatorcontrib>Viikari, Jorma S.A.</creatorcontrib><creatorcontrib>Mueller, Thomas</creatorcontrib><creatorcontrib>Kronenberg, Florian</creatorcontrib><creatorcontrib>Paulweber, Bernhard</creatorcontrib><creatorcontrib>Lehtimäki, Terho</creatorcontrib><creatorcontrib>Zoller, Heinz</creatorcontrib><creatorcontrib>Raitakari, Olli T.</creatorcontrib><creatorcontrib>Dieplinger, Hans</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pitkänen, Niina</au><au>Finkenstedt, Armin</au><au>Lamina, Claudia</au><au>Juonala, Markus</au><au>Kähönen, Mika</au><au>Mäkelä, Kari-Matti</au><au>Dieplinger, Benjamin</au><au>Viveiros, Andre</au><au>Melmer, Andreas</au><au>Leitner, Isabella</au><au>Kedenko, Ludmilla</au><au>Seppälä, Ilkka</au><au>Viikari, Jorma S.A.</au><au>Mueller, Thomas</au><au>Kronenberg, Florian</au><au>Paulweber, Bernhard</au><au>Lehtimäki, Terho</au><au>Zoller, Heinz</au><au>Raitakari, Olli T.</au><au>Dieplinger, Hans</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clin Chem Lab Med</addtitle><date>2022-01-27</date><risdate>2022</risdate><volume>60</volume><issue>2</issue><spage>243</spage><epage>251</epage><pages>243-251</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD.
Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up.
Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23-1.54] per 10 mg/L increase, p<0.0001).
Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort.</abstract><cop>Germany</cop><pub>De Gruyter</pub><pmid>34850615</pmid><doi>10.1515/cclm-2021-0837</doi><tpages>09</tpages><orcidid>https://orcid.org/0000-0002-4484-8471</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1434-6621 |
| ispartof | Clinical chemistry and laboratory medicine, 2022-01, Vol.60 (2), p.243-251 |
| issn | 1434-6621 1437-4331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2605230968 |
| source | MEDLINE; De Gruyter journals |
| subjects | Adult afamin Austria - epidemiology Cardiovascular diseases Carrier Proteins - blood Diabetes mellitus (non-insulin dependent) Fatty liver Female Finland - epidemiology Glycoproteins - blood Health risks Humans Incidence Liver Liver diseases Male Metabolic disorders Metabolic syndrome Non-alcoholic Fatty Liver Disease - blood Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - epidemiology non-alcoholic liver disease Population Population-based studies prediction Prevalence Regression analysis Risk Factors Serum Albumin, Human Sex vitamin E-binding protein |
| title | Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T00%3A58%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Afamin%20predicts%20the%20prevalence%20and%20incidence%20of%20nonalcoholic%20fatty%20liver%20disease&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=Pitk%C3%A4nen,%20Niina&rft.date=2022-01-27&rft.volume=60&rft.issue=2&rft.spage=243&rft.epage=251&rft.pages=243-251&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/cclm-2021-0837&rft_dat=%3Cproquest_cross%3E2605230968%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616445347&rft_id=info:pmid/34850615&rfr_iscdi=true |